SchapiraAHV, ObesoJ. Timing of treatment initiation in Parkinson's disease: a need for reappraisal?Ann Neurol., 2006; 59:559–562.
2.
AcquasE, TandaG, Di ChiaraG. Differential effects of caffeine on dopamine and acetylcholine transmission in brain areas of drug-naive and caffeine-pretreated rats. Neuropsychopharmacology., 2002; 27:182–193.
3.
AscherioA, WeisskopfMG, O'ReillyEJ, McCulloughML, CalleEE, RodriguezC, ThunMJ. Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. Am J Epidemiol., 2004; 160:977–984.
4.
CorleyJ, JiaX, KyleJAM, GowAJ, BrettCE, StarrJM, McNeillG, DearyIJ. Caffeine consumption and cognitive function at age 70: The Lothian Birth Cohort 1936 Study. Psychosom Med., 2010; 72:206–214.
5.
RossGW, AbbottRD, PetrovitchH, MorensDM, GrandinettiA, TungKH, TannerCM, MasakiKH, BlanchettePL, CurbJD, PopperJS, WhiteLR. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA., 2000; 283:2674–2679.
6.
SimonDK, SwearingenCJ, HauserRA, TrugmanJM, AminoffMJ, SingerC, TruongD, TilleyBC. NET-D Investigators. Caffeine and progression of Parkinson disease. Clin Neuropharmacol., 2008; 31:189–196.
